Morning Report | Gulf shipping risk repriced, crude volatility into the Fed
$XLE crude whips on Gulf risk $TLT duration bid meets Fed risk $AAPL earnings tape, iPhone pricing watch $MSFT earnings tape, AI capex scrutiny $TAN FCC Covered List expands
Market Pulse
U.S.-Iran War
5 events
Missile and drone exchanges around U.S. forces and Iraq-based militias reprice Gulf shipping risk, keeping crude volatile into the Fed.
Latest Development
CENTCOM said Iran fired multiple ballistic missiles at U.S. forces, all intercepted; it said U.S. and Saudi forces struck logistics and weapons sites in eastern Iraq, while PMF claimed 20 killed and 32 wounded.
In Asia trade, Brent September futures rose 3.48% to about $87.02/bbl and WTI gained 3.34% to about $81.91/bbl, with Red Sea ‘suspicious activity’ flagged by UKMTO.
Reuters reported Oman floated a Gulf-backed framework that could let Iran collect ‘voluntary’ vessel fees for Strait of Hormuz transits; the American Petroleum Institute opposed any new tolls.
Iran said it discussed Strait of Hormuz insecurity with Saudi Arabia and Oman; in that session Brent fell 4.8% to $84.09 and WTI 4.0% to $79.26 while U.S. yields dipped (10Y 4.606%, 2Y 4.281%).
Reuters cited three sources saying Iran expects an initial shipment within weeks under a $60–70 million contract for 300–400 Chinese MANPADS via a Hong Kong intermediary; China called the report groundless and Pakistan denied involvement.
Market reaction
Crude whipsawed: after Monday’s de-escalation tape pushed Brent to $84.09 (-4.8%) and WTI to $79.26 (-4.0%), fresh missile/strike headlines lifted Brent Sep to ~$87.02 (+3.48%) and WTI to ~$81.91 (+3.34%) in Asia; U.S. yields were lower (10Y 4.606%, 2Y 4.281%).
Our view
The market keeps a meaningful but tradable geopolitical premium in crude rather than pricing a sustained physical supply shock. Monitor whether Hormuz transit-fee proposals harden into enforcement and whether Red Sea/Hormuz security incidents or further missile/drone exchanges broaden beyond current tit-for-tat.
What could change our view
Enforced Hormuz fees or direct hits disrupt shipping, triggering sustained crude repricing.
Durable ceasefire framework and verified de-escalation compress the risk premium quickly.
Tickers: $TLT, $XLE, $CL=F
Mega-cap
3 events
Apple and Microsoft earnings set near-term tone for mega-cap tech as iPhone pricing, margins and AI capex monetization face heightened scrutiny.
Latest Development
Reuters flagged Apple holding iPhone prices through April–June, with LSEG consensus looking for June-quarter revenue +15.5% YoY to $108.65B and profit +18.1% YoY.
Apple raised iPad and MacBook prices last month citing memory/storage chip shortages tied to AI datacenter buildouts; consensus gross margin is seen at 47.9% versus 49.3% prior quarter.
Reuters/ORATS said Microsoft options imply a ±6.6% post-earnings move (~$190B market-cap swing) versus a 12-cycle average 4.8%, with focus on Azure growth and AI tools uptake versus capex intensity.
Market reaction
Ahead of earnings, Apple briefly reached a ~$5T market cap with an intraday high of $342.89 before closing at $340.08, leaving it just below the milestone.
Our view
Elevated index-level volatility around MSFT and AAPL prints, with outcomes hinging on near-term margin resilience at Apple and evidence AI spending is translating into Microsoft cloud and tool demand. The key monitor is forward commentary on iPhone pricing versus component-cost inflation and Azure/AI revenue traction relative to capex.
What could change our view
Apple indicates iPhone price-hold is ending sooner, pressuring demand expectations.
Microsoft commentary reinforces capex intensity without clearer Azure or AI monetization.
Tickers: $AAPL, $MSFT
Macro & Policy Digest
Russia-Ukraine headlines refocus on energy disruption as US Senate advances tougher Russia sanctions while Ukrainian drones hit refineries and logistics.
Latest Development
The US Senate voted 86–12 to advance a Russia/Iran sanctions bill, proposing primary and secondary sanctions plus presidential tariff authority on countries buying Russian oil and gas.
Overnight Ukrainian drones struck refineries and logistics sites in Perm, Ryazan and Taganrog and targets in Crimea; retailer Wildberries halted deliveries after warehouse damage, saying recent attacks hit about 10% of storage capacity.
Our view
Near-term energy complex trades higher in risk premium but without a sustained supply shock, given policy discretion and episodic infrastructure hits. Monitor whether the sanctions package progresses to enactment and is applied to buyers/shipping in ways that constrain export flows.
What could change our view
Sanctions bill stalls or is watered down via broad waivers.
Refinery and logistics hits escalate into sustained export or product outages.
Tickers: $XLE, $BZ=F
Medicare Part D subsidy sunset and an AHRQ grant freeze raise policy-driven uncertainty for managed-care and healthcare services into 2027 bids.
Latest Development
Reuters/WSJ report the administration will not renew Medicare Part D premium-stabilization subsidies after 2026; the program is expected to pay insurers about $3.6B in 2026.
HHS’ AHRQ told researchers it is halting at least 104 patient-safety grants; CBS says under a $345M appropriation it has spent under $15M on grants, with staffing down to ~74 from ~300.
Our view
Healthcare policy volatility stays elevated, with managed-care and PBM-exposed names most sensitive as 2027 Part D pricing and benefit decisions are set. Key monitor is forthcoming CMS/HHS bid-cycle guidance and any shift in the reported subsidy sunset, alongside whether AHRQ’s promised new grant framework or litigation changes the funding pause.
What could change our view
CMS accelerates or broadens Part D subsidy rollback beyond the post-2026 plan.
AHRQ funding pause reverses quickly, reducing perceived policy tightening across healthcare.
Tickers: $XLV
FCC adds foreign-made power inverters and advanced robotic devices to Covered List, tightening US equipment authorizations across solar DER and robotics supply chains.
Latest Development
• FCC placed foreign-produced power inverters and foreign-produced advanced robotic devices on its Covered List, making new models generally ineligible for fresh equipment authorizations needed to market or sell in the US.
Our view
This expands national-security screening into inverter and robotics hardware, raising compliance and sourcing costs for new foreign-made models and favoring already-authorized products. Key monitor is how broadly the FCC applies authorization denials and whether additional device categories are added via the interagency process.
What could change our view
FCC scope remains narrow to select models, limiting real supply-chain impact.
Rules broaden or become retroactive, disrupting installed bases and project timelines.
Tickers: $TAN
Company Events
AI chip equities are in a global de-risking downdraft as memory earnings misses and ETF drawdowns amplify volatility.
Latest Development
A CNBC/FactSet tally put ~$1.3T erased from 20 top chip stocks since Friday’s close; SOX is ~20% lower in a month, with SOXX ~25% off June 22 and SOXL ~63% down.
SK Hynix reported record Q2 operating profit of Won 60.5tn on Won 79.3tn revenue but missed a Won 64tn SmartEstimate; shares ended ~10% lower after a 15–20% intraday drop.
Market reaction
Semis have sold off hard: SOXX is ~25% below its June 22 peak and SMH fell >2% in the latest U.S. session cited, while SOXL is down ~63%. In Korea, SK Hynix slid ~10% and the KOSPI closed down ~6% after a much deeper intraday drawdown.
Our view
The AI chip complex stays in de-risking mode with downside skew, led by memory sensitivity and leveraged-ETF volatility. We watch for whether upcoming results and capex signals reverse the miss narrative and whether SOXX can hold above recent lows.
What could change our view
Memory earnings and demand signals re-accelerate, forcing a rapid risk-on reversal.
Further estimate misses or higher capex stoke deeper cyclicality fears in SOXX.
Tickers: $SOXX, $MU
Ford and UPS earnings upgrades support industrial cyclicals, but tariff-timing cash and flat Q3 domestic revenue keep quality-of-growth in focus.
Latest Development
Ford beat Q2 expectations as revenue fell 4% YoY to $48.3B, and raised 2026 adjusted EBIT to $10B–$11B and adjusted FCF to $6B–$7B including earlier $500M tariff reimbursement cash recovery.
UPS beat Q2 and lifted its full-year outlook to $91.2B revenue and about $7.22 adjusted EPS, while guiding Q3 U.S. domestic revenue flat YoY with average daily volume down mid-single digits amid the Amazon glide-down and network reconfiguration.
Market reaction
Ford shares rose about 7% in after-hours trading following the Q2 beat and higher 2026 guidance.
Our view
Treat the prints as modestly constructive for autos and parcel/transport, with guidance raises doing more for sentiment than for near-term demand expectations. Watch whether Ford’s higher FCF persists beyond the $500M timing benefit and whether UPS’s reconfiguration savings offset Q3 domestic volume pressure.
What could change our view
Ford pricing or mix deteriorates, pushing EV losses and EBIT below raised range.
UPS network savings miss targets while Q3 domestic volume declines exceed mid-single digits.
Tickers: $F, $UPS
Biogen beat Q2 estimates but reset 2026 adjusted EPS range lower on acquisition charges as Leqembi grew and MS erosion persisted.
Latest Development
Biogen posted Q2 adjusted EPS $3.60 on $2.74B revenue versus estimates, then cut 2026 adjusted EPS to $12–$13 citing ~$3.85/share acquisition-related charges; Leqembi sales rose 15% y/y to ~$184M.
Our view
We expect the print to be read as operationally solid but valuation capped by the 2026 EPS range now centered around consensus and burdened by acquisition charges. Next check is whether Apellis integration keeps the stated ~$0.85/sh annual profit hit contained and whether the new U.S. subcutaneous Leqembi launch sustains uptake against ongoing Tecfidera decline.
What could change our view
Acquisition-related charges or Apellis profit drag exceeds management’s quantified impacts.
Leqembi uptake disappoints or MS franchise erosion accelerates beyond current pressure.
Tickers: $BIIB
Humana’s Q2 EPS beat but in-line medical costs and unchanged full-year outlook raise the bar for Medicare Advantage margin improvement.
Latest Development
Humana posted Q2 adjusted EPS $7.61 vs $7.22 expected, reported MCR 91.2% versus 91.19% estimate, kept full-year adjusted profit outlook unchanged, and was down about 9% in premarket trading.
Market reaction
Humana shares were down about 9% in premarket despite the EPS beat, with the in-line MCR and unchanged full-year outlook read as limited upside versus elevated expectations.
Our view
Payer sentiment stays fragile as in-line medical cost trends and unchanged guidance keep focus on cost control and risk adjustment rather than headline beats. Next key monitor is whether subsequent updates show clear MCR improvement relative to rising utilization and tighter Medicare Advantage reimbursement.
What could change our view
Meaningful MCR improvement and upward profit guidance reset expectations higher.
Evidence of worsening utilization drives MCR above expectations and forces guidance cuts.
Tickers: $HUM
Bunge lifts 2026 EPS outlook after a Q2 beat as higher corn/soy prices and strong crush margins boost processing economics.
Latest Development
• Bunge raised 2026 adjusted EPS to $9.25–$9.75 (from $9.00–$9.50) after a Q2 beat, with soybean and softseed processing sales up ~56% and ~167% y/y.
Our view
BG’s raised 2026 outlook is credible if crush/processing margins stay supported by higher corn/soy prices and throughput. Key monitor is margin persistence into 2H as Midwest grain selling flows and ethanol-linked demand dynamics evolve with war-driven moves in crude.
What could change our view
Crush/processing margins normalize sharply, undercutting elevated segment economics and EPS trajectory.
Corn/soy price reversal slows farmer selling and reduces processing volumes.
Tickers: $BG
Go deeper -
For intraday developments, follow our Midday posts.
For the close, the wrap, and next-day trade ideas, read the Evening Memo.
For deeper work, Forward Valuation covers multi-week single-name setups (paid subscribers only).
Deep Dive is where we publish our full thematic research for paid subscribers.
Informational only; not investment advice. Sources deemed reliable.